Free tool
FAERS Monitor: Butrans
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021306 or its brand name (Butrans, Buprenorphine). Reports on generic versions are filed under their own applications.
Reports
84,822
Serious
53,931
64% of reports
Hospitalization
10,686
Death reported
26,428
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death13,389
- drug dependence12,078
- overdose10,916
- toxicity to various agents10,759
- pain8,180
- drug ineffective6,221
- drug withdrawal syndrome5,754
- emotional distress5,448
- nausea4,248
- drug abuse3,588
- inadequate analgesia3,049
- application site rash3,025
- product adhesion issue2,881
- dizziness2,676
- rash2,542
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 34 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 37 |
| 2010 | 96 |
| 2011 | 426 |
| 2012 | 667 |
| 2013 | 13,502 |
| 2014 | 5,252 |
| 2015 | 4,559 |
| 2016 | 3,033 |
| 2017 | 4,504 |
| 2018 | 22,273 |
| 2019 | 2,613 |
| 2020 | 3,991 |
| 2021 | 8,152 |
| 2022 | 5,243 |
| 2023 | 2,351 |
| 2024 | 2,866 |
| 2025 | 3,245 |
| 2026 | 1,966 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,969,337 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inadequate analgesiaSignal | 3,049 | 138.2 | 132.3 | 266,405 |
| application site rashSignal | 3,025 | 69.6 | 66.9 | 159,707 |
| product adhesion issueSignal | 2,881 | 21.7 | 20.9 | 52,265 |
| drug dependenceSignal | 12,078 | 20.1 | 19.7 | 203,816 |
| drug withdrawal syndromeSignal | 5,754 | 17.3 | 16.9 | 83,073 |
| toxicity to various agentsSignal | 10,759 | 16.8 | 16.5 | 151,171 |
| overdoseSignal | 10,916 | 13.2 | 12.9 | 117,679 |
| emotional distressSignal | 5,448 | 11.6 | 11.3 | 50,870 |
| drug abuseSignal | 3,588 | 11.1 | 10.8 | 31,752 |
| deathSignal | 13,389 | 3.9 | 3.8 | 29,618 |
| painSignal | 8,180 | 3.3 | 3.3 | 13,575 |
| rash | 2,542 | 1.4 | 1.4 | 358 |
| nausea | 4,248 | 1.3 | 1.3 | 364 |
| dizziness | 2,676 | 1.3 | 1.3 | 225 |
| drug ineffective | 6,221 | 1.2 | 1.1 | 165 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.